Premedication and Infusion Reactions With Infliximab: Results From a Pediatric Inflammatory Bowel Disease Consortium
Open Access
- 1 May 2005
- journal article
- research article
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 11 (5) , 442-446
Abstract
Background. Infusion reactions (IRs) are the most common adverse events associated with the use of infliximab for inflammatory bowel disease (IBD). AntipyreticKeywords
This publication has 12 references indexed in Scilit:
- Efficacy and Tolerance of Infliximab in Children and Adolescents with Crohn’s DiseaseInflammatory Bowel Diseases, 2004
- Comparison of scheduled and episodic treatment strategies of infliximab in Crohn’s diseaseGastroenterology, 2004
- The safety profile of infliximab in patients with Crohn’s disease: The Mayo Clinic experience in 500 patientsGastroenterology, 2004
- The Incidence and Management of Infusion Reactions To Infliximab: A Large Center ExperienceAmerican Journal of Gastroenterology, 2003
- Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's DiseaseNew England Journal of Medicine, 2003
- Infliximab retreatment in adults and children with Crohn's disease: risk factors for the development of delayed severe systemic reactionAmerican Journal of Gastroenterology, 2002
- Efficacy and safety of repeated infliximab infusions for Crohn's disease: 1-year clinical experienceInflammatory Bowel Diseases, 2001
- Infliximab for Crohn's disease in clinical practice at the Mayo Clinic: the first 100 patientsAmerican Journal of Gastroenterology, 2001
- Infliximab for the Treatment of Fistulas in Patients with Crohn's DiseaseNew England Journal of Medicine, 1999
- Antibody to Tumor Necrosis Factor in the Treatment of Crohn's DiseaseJournal of Pediatric Gastroenterology and Nutrition, 1998